Study of the Efficiency of Hydroxychloroquine on the Endothelial Dysfunction and Its Vascular Consequences During the Antiphospholipid Syndrome

NCT02595346 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

OTHER

Sponsor class

Stopped Difficulty in enrolling new patients

Conditions

Antiphospholipid Syndrome (APS)

Interventions

DRUG: Hydroxychloroquine
DRUG: placebo

Sponsor

University Hospital, Rouen